ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UroGen To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - June 1, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UroGen Pharma Ltd. ('UroGen' or the 'Company') (NASDAQ: URGN) and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/6455/254027_a7b28fc334d2babd_001full.jpg ]
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA's warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On May 16, 2025, before the market opened, the U.S. Food and Drug Administration ('FDA') published a briefing document in advance of its Oncologic Drugs Advisory Committee meeting regarding UroGen's new drug application ('NDA') for UGN-102, which stated the agency doubted whether the submitted data was sufficient to conclude that UGN-102 was effective. In the briefing document, the FDA stated: "[g]iven that [the ENVISION trial] lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret.' The FDA also said it had 'recommended a randomized trial design to the Applicant several times during their product's development due to concerns with interpreting efficacy results' but UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.'
On this news, UroGen's stock price fell $2.54, or 25.8%, to close at $7.31 per share on May 16, 2025, on unusually heavy trading volume.
Then, on May 21, 2025, before the market opened, the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA. The committee found that the overall benefit-risk of the investigational therapy UGN-102 (intravesical mitomycin) is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.
On this news, UroGen's stock price fell $3.37, or 44.7%, to close at $4.17 per share on May 21, 2025, on unusually heavy trading volume.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding UroGen's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the UroGen Pharma Ltd. class action, go to www.faruqilaw.com/URGN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254027
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
25 minutes ago
- Associated Press
Dodgers' Tyler Glasnow is optimistic about recovery from shoulder injury
LOS ANGELES (AP) — Tyler Glasnow is feeling optimistic about his recovery from a shoulder injury that has sidelined him since late April, one of five Los Angeles Dodgers starting pitchers who are on the injured list. There's no timetable yet for his return. The 31-year-old right-hander got hurt against Pittsburgh on April 27. He was recently moved to the 60-day IL. 'My shoulder is totally fine,' he said Tuesday. Glasnow downplayed the general body soreness that manager Dave Roberts mentioned on Monday. He said back tightness after a bullpen session prompted a precautionary decision to rest him for a few days. 'We're both on the same wavelength,' he said of himself and the team. His shoulder feels better, he said, and he plans to throw a bullpen session later this week. He played catch in the outfield Tuesday. 'I'll be back as soon as I can in a healthy way to help the team in the playoffs is my goal,' he said. Last season, Glasnow didn't pitch in the postseason because of right elbow tendinitis. He signed a $135.5 million, five-year deal before the 2024 season. Also Tuesday, the Dodgers signed right-hander José Ureña, who was designated for assignment last weekend by Toronto. He was 0-0 with a 3.65 ERA in six appearances for the Blue Jays. He began the season with the New York Mets, giving up five runs in three innings of his lone appearance. Ureña, 33, has spent 11 years in the majors with Miami, Detroit, Milwaukee, Colorado, the Chicago White Sox, Texas, the Mets and Blue Jays. He is 44-77 with a 4.78 ERA in 239 games. The Dodgers also optioned right-handed pitcher Will Klein to Triple-A Oklahoma City and designated catcher Chuckie Robinson for assignment. ___ AP MLB:
Yahoo
25 minutes ago
- Yahoo
Knicks rumors: Bill Simmons floats Kevin Durant trade proposal
The post Knicks rumors: Bill Simmons floats Kevin Durant trade proposal appeared first on ClutchPoints. After the New York Knicks lost in the Eastern Conference Finals to the Indiana Pacers in six games, the focus now is an analysis on how they can improve going into the offseason. With the Knicks already surrounded by rumors, Bill Simmons would have an interesting trade proposal that is sure to have fans possibly scratching their heads. Advertisement His trade surrounds star Karl-Anthony Towns, where he would say a one-for-one deal where he is sent to the Phoenix Suns for forward Kevin Durant. Simmons would point to the connection between Towns and Suns guard Devin Booker and how they have 'known each other since they were kids.' 'Let me throw this one at you, Towns for Durant,' Simmons said on his self-titled show. 'I think Durant has a year left, but you can extend him. The salaries actually work as a one-for-one. Towns, if you remember, has a whole friendship history with Booker. Like they've known each other since they were kids, they have the same agent. I remember we got pitched this at The Ringer in 2019. Towns, Booker, and Russell all wanted to do a podcast together, and they all lived in different places, and we were like, there's no way. Like now we would have the technology.' Bill Simmons further explains how the Knicks can get Kevin Durant Kirby Lee-Imagn Images While fans have already made some trade proposals with the Knicks star in Towns, this one returns an elite player like Durant, though it would be understood that he's in the twilight years of his career. Simmons would argue that it's almost a win-win scenario for each team as Phoenix gets back a highly productive player in Towns and New York gets an impact player in Durant. Advertisement 'If they don't have a ton of outs with Durant, and if you're the Suns, you don't have a lot of ways to get better,' Simmons said. 'If Booker loves Towns, and I think they're still buddies, is that a way to get out of the Durant business. Then, if you're the Knicks, you have this one-year run with Durant. You can talk yourself into Mitchell Robinson 30 minutes a game. You're out of the Towns' defense business; you kind of sold high. You got out of Randle, you got out of Towns with this big contract coming.' Last season in his first with the Knicks, Towns averaged 24.4 points, 12.8 rebounds, and 3.1 assists per game while shooting 52.6 percent from the field and 42 percent from beyond the arc. It remains to be seen what happens with Towns, but New York looks to improve after losing to Indiana in the Eastern Conference Finals.
Yahoo
25 minutes ago
- Yahoo
Draymond Green doubts Knicks can win title without ‘great player'
The post Draymond Green doubts Knicks can win title without 'great player' appeared first on ClutchPoints. Golden State Warriors forward Draymond Green cast doubt on the New York Knicks' championship outlook in the aftermath of their Eastern Conference Finals exit, emphasizing the need for a true star to lead the franchise to a title. Advertisement Green addressed the Knicks' future on a recent episode of The Draymond Green Show, stating bluntly that New York is still not equipped to win it all. 'As far as the Knicks going forward, I think going forward in order to win it ain't there yet,' Green said. 'I just don't foresee it. I think in order to win the Knicks need to bring in a great player. I can't talk specific names because I'm not going to give my money away for that, but if the Knicks want to compete for a championship I think they need a great player.' The comments follow the Knicks' elimination by the Indiana Pacers in six games, cutting short a postseason run that saw the franchise reach the Eastern Conference Finals for the first time since 2000. Despite making key additions last offseason — most notably Mikal Bridges and Karl-Anthony Towns — New York ultimately fell short in its bid to return to the NBA Finals. Despite Jalen Brunson's playoff brilliance, Draymond Green says Knicks need a 'great player' Trevor Ruszkowski-Imagn Images Jalen Brunson once again delivered an elite postseason performance. The All-NBA guard averaged 29.4 points, seven assists and 3.4 rebounds while shooting 46.1% from the field and 35.8% from three-point range across 18 games. He played 37.8 minutes per contest and carried much of the offensive load. Advertisement Still, the absence of another top-tier shot creator or All-NBA-caliber star appeared to loom large in the series loss to Indiana. In the aftermath of the season-ending defeat, ESPN's Shams Charania reported on SportsCenter that the Knicks are conducting internal meetings this week to evaluate their path forward. 'I'm told the Knicks have internal meetings this week to really evaluate everything from their coaches to their players and just see how they move forward to continue to compete for a championship in the Eastern Conference,' Charania said. 'But if we've seen the last year and a half as any indication, for Leon Rose, the Knicks president, went out and got OG Anunoby, Mikal Bridges, and Karl-Anthony Towns to elevate this team. I do expect the Knicks to be aggressive to see, is there a move out there, a landmark move, potentially, that takes this team over the top, or do they just make moves around the edges for their bench?' Knicks part ways with Tom Thibodeau as pursuit of star talent like Giannis or Durant looms New York has already made a significant change, firing head coach Tom Thibodeau on Tuesday, according to Charania. Thibodeau, hired ahead of the 2020-21 season, led the team to four playoff appearances in five years, missing only in 2021-22. Advertisement Ian Begley of SNY reported that the organization holds 'great respect for Thibodeau and what he did for [the] Knicks, but simply felt a new voice was needed.' The Knicks have been linked to potential trade pursuits of Milwaukee Bucks forward Giannis Antetokounmpo and Phoenix Suns star Kevin Durant. As the team prepares for the 2025-26 season, Green's remarks reflect a broader belief that one more elite player may be the missing piece.
